Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
21 hedge funds and large institutions have $371K invested in Titan Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
72% more capital invested
Capital invested by funds: $216K → $371K (+$155K)
24% more funds holding
Funds holding: 17 → 21 (+4)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$110K |
| 2 |
VF
Virtu Financial
New York
|
+$97.6K |
| 3 |
Renaissance Technologies
New York
|
+$64.3K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$36.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$84.6K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$22K |
| 3 |
HF
HRT Financial
New York
|
-$5K |
| 4 |
Goldman Sachs
New York
|
-$3K |
| 5 |
WPA
Winning Points Advisors
Boca Raton,
Florida
|
-$3K |
TTNP Hedge Fund Activity: Q4 2019 in Review
21 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2019, worth a combined $371K — up 72% from $216K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TTNP positions and 5 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $110K. The largest seller was Vanguard Group, cutting an estimated $84.6K.
- 21 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2019, up from 17 in Q3 2019.
- Funds reported $371K of Titan Pharmaceuticals stock for Q4 2019, up 72% quarter-over-quarter.
- 9 funds opened new Titan Pharmaceuticals positions in Q4 2019 and 5 closed out, a net change of +4 holders.
- The largest Titan Pharmaceuticals buyer in Q4 2019 was Susquehanna International Group, an estimated $110K added.
- The largest Titan Pharmaceuticals seller in Q4 2019 was Vanguard Group, an estimated $84.6K sold.
Based on aggregated 13F filings for Q4 2019.